Home Cart Sign in  
Chemical Structure| 911715-90-7 Chemical Structure| 911715-90-7

Structure of AZD8797
CAS No.: 911715-90-7

Chemical Structure| 911715-90-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AZD8797 (KAND567) is an allosteric, non-competitive, orally active antagonist of the human CX3CR1 receptor, with Kis of 3.9 nM and 2800 nM for CX3CR1 and CXCR2, respectively.

Synonyms: KAND567

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AZD8797

CAS No. :911715-90-7
Formula : C19H25N5OS2
M.W : 403.56
SMILES Code : CC(C)C[C@@H](NC1=C(SC(N)=N2)C2=NC(S[C@H](C3=CC=CC=C3)C)=N1)CO
Synonyms :
KAND567
MDL No. :MFCD28139065

Safety of AZD8797

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P313-P337+P313-P362-P403+P233-P405-P501

Related Pathways of AZD8797

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
CHO-hCX3CR1 cells 340 nM (IC50) 1 hour Evaluate the inhibitory effect of AZD8797 on CX3CL1-induced [35S]GTPγS accumulation, results showed AZD8797 effectively inhibited G-protein activation. PMC4764977
CHO-hCX3CR1 cells 340 nM (IC50) 1 hour Evaluate the inhibitory effect of AZD8797 on CX3CL1-induced [35S]GTPγS accumulation, results showed AZD8797 effectively inhibited G-protein activation. PMC4764977
RPMI-8226 cells 5.8 nM (IC50) 15 minutes Evaluate the inhibitory effect of AZD8797 on the adhesion of RPMI-8226 cells to CX3CL1, results showed AZD8797 effectively inhibited cell adhesion. PMC4764977
RPMI-8226 cells 5.8 nM (IC50) 15 minutes Evaluate the inhibitory effect of AZD8797 on the adhesion of RPMI-8226 cells to CX3CL1, results showed AZD8797 effectively inhibited cell adhesion. PMC4764977
Alveolar macrophages 10 ng/ml or 100 ng/ml 24 hours IL-21 significantly upregulated M2 macrophage polarization and Fizz1 protein levels PMC11619207
Human whole blood leucocytes 330 nM (IC50) 60 minutes Evaluate the inhibitory effect of AZD8797 on the adhesion of human whole blood leucocytes to CX3CL1, results showed AZD8797 effectively inhibited cell adhesion. PMC4764977
Human whole blood leucocytes 330 nM (IC50) 60 minutes Evaluate the inhibitory effect of AZD8797 on the adhesion of human whole blood leucocytes to CX3CL1, results showed AZD8797 effectively inhibited cell adhesion. PMC4764977

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice OVCAR-4 xenograft model Oral gavage 0.625 mg/mouse Once daily for three weeks The combination of AZD8797 and olaparib showed synergy in reducing tumor burden PMC11591600
Nude mice OVCAR-4 xenograft model Oral gavage 0.625 mg/mouse (AZD8797), 0.25 mg/mouse (olaparib) Once daily for three weeks The combination of AZD8797 and olaparib showed synergy in reducing tumor burden PMC11591600
Sprague-Dawley rats Status epilepticus model Intraperitoneal injection 1 mg/kg Once per day for four days AZD8797 reversed the decline in nociceptive behaviour in comorbid rats and reduced the number of iba1-positive microglia and microglial activation in rats with migraine after seizures PMC8981829
C57BL/6 mice Intracerebral hemorrhage model Lateral ventricular injection 100 μmol/μl Single injection, lasting for 3 days AZD8797 increased hematoma volume and worsened neurological deficit score PMC11072118
C57BL/6J mice Pharmacologically induced retinal degeneration model Intravitreal injection 3.125 ng/μL Single injection, evaluated at 14 and 28 days post-treatment AZD8797 preserved retinal structure and enhanced photoreceptor survival by inhibiting CX3CL1/CX3CR1 expressions. Fundus photography showed clear retinal vessel distribution and reduced lesion severity. Morphological improvements translated into functional enhancements, as evidenced by behavioral tests and electroretinogram (mf-ERG) examinations. Mechanistic studies showed AZD8797 mitigated microglial activation and migration in degenerative retinas. Müller cell hyper-reaction and secondary gliosis were also suppressed by AZD8797. PMC10795588
Sprague-Dawley rat pups Bacterial collagenase-induced GMH model Intracerebroventricular injection 39 μmol/kg Single dose AZD8797 reversed the protective effects of r-FKN, increased hemoglobin content, reduced M2 microglia polarization, and increased pro-inflammatory cytokine expression. PMC10453335
Dark Agouti rats MOG 1-125-induced EAE model Subcutaneous injection 60-78 μmol/kg/24h Continuous for 14-28 days AZD8797 treatment significantly reduced paralysis, CNS pathology, and incidence of relapses in EAE rats. PMC3986185
Adult male Sprague-Dawley rats Spinal cord injury model Intraperitoneal injection 80 µg/kg Once per day until the rats were sacrificed AZD8797 improved locomotive recovery after spinal cord injury by suppressing apoptosis, necrosis, and inflammatory responses PMC7138267

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.48mL

0.50mL

0.25mL

12.39mL

2.48mL

1.24mL

24.78mL

4.96mL

2.48mL

 

Historical Records

Categories